title: Therapeutic versus prophylactic plus therapeutic administration of omega-3 fatty acid on endotoxin-induced periodontitis in rats.
abstract: BACKGROUND
  The aim of the present study was 1) to evaluate the possible effects of therapeutic usage of omega-3 fatty acid on the gingival tissue levels of prostaglandin E2 (PGE2), prostaglandin F2alpha (PGF2alpha), platelet activating factor (PAF), and leukotriene B4 (LTB4) in endotoxin-induced periodontitis in rats and 2) to investigate whether prophylactic usage provides any additional benefits to therapeutic doses of omega-3 fatty acid.
  
  
  METHODS
  Experimental periodontitis was induced by repeated injection of Escherichia coli lipopolysaccharide (LPS). Thirty-six adult male Sprague-Dawley rats were divided into four study groups: 1) saline controls; 2) LPS; 3) therapeutic omega-3 fatty acid (TO3); and 4) prophylactic plus therapeutic omega-3 fatty acid (P + TO3) groups. In TO3 group, omega-3 fatty acid was given for 15 days following induction of experimental periodontitis. In P + TO3 group, omega-3 fatty acid was started 15 days before baseline, and then periodontitis was induced at baseline and omega-3 fatty acid was continued for 15 days after baseline. On day 15 after baseline, all rats were anesthetized and sacrificed. PGE2, PGF2alpha, and LTB4 levels in gingival tissue samples were analyzed by enzyme immunoassay and PAF levels were analyzed by radioimmonoassay. Data were evaluated statistically by using parametric tests.
  
  
  RESULTS
  LPS injection resulted in significant amount of bone loss (P<0.05). Neither therapeutic nor prophylactic plus therapeutic administration of omega-3 fatty acid with the doses and duration of therapy used in the present study was effective in preventing endotoxin-induced alveolar bone loss. TO3 group exhibited significant decreases in the gingival tissue levels of PGE2, PGF2alpha, LTB4, and PAF compared to the LPS group (P<0.05). PGE2 and PGF2alpha levels in TO3 group were similar to those of the saline group (P>0.05), while LTB4 and PAF levels were statistically higher than the saline group (P<0.05). Prophylactic plus therapeutic usage of omega-3 fatty acid provided similar levels of all these mediators to those of the saline controls (P>0.05).
  
  
  CONCLUSIONS
  Therapeutic omega-3 fatty acid significantly reduced the gingival tissue levels of PGE2, PGF2alpha, LTB4, and PAF in experimental periodontitis. Furthermore, prophylactic usage of omega-3 fatty acid provided additional beneficial effects to the therapeutic administration by decreasing the gingival tissue levels of these mediators to levels of healthy tissue. These findings should be verified by longitudinal clinical trials investigating clinical and biochemical periodontal parameters to better define the possible role of omega-3 fatty acids in periodontal treatment.
authors.affiliation: Ege University, School of Dentistry, Department of Periodontology, Izmir, Turkey. saynurvardar@yahoo.com
authors.forename: Saynur
authors.initials: S
authors.lastname: Vardar
authors.forename: Eralp
authors.initials: E
authors.lastname: Buduneli
authors.forename: Oya
authors.initials: O
authors.lastname: Türkoğlu
authors.forename: Afig Hüseyinov
authors.initials: AH
authors.lastname: Berdeli
authors.forename: Haluk
authors.initials: H
authors.lastname: Baylas
authors.forename: Aykut
authors.initials: A
authors.lastname: Başkesen
authors.forename: Gül
authors.initials: G
authors.lastname: Atilla
mesh_terms: D016301:Alveolar Bone Loss / Q000378:metabolism / Q000517:prevention & control*; D000704:Analysis of Variance; D000818:Animals; D015237:Dinoprost / Q000032:analysis / Q000096:biosynthesis; D015232:Dinoprostone / Q000032:analysis / Q000096:biosynthesis; D004731:Endotoxins / Q000494:pharmacology; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use*; D005881:Gingiva / Q000737:chemistry / Q000378:metabolism; D007124:Immunoenzyme Techniques; D018836:Inflammation Mediators / Q000378:metabolism*; D007975:Leukotriene B4 / Q000032:analysis / Q000096:biosynthesis; D008297:Male; D010518:Periodontitis / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism*; D010972:Platelet Activating Factor / Q000032:analysis / Q000096:biosynthesis; D011863:Radioimmunoassay; D051381:Rats; D017207:Rats, Sprague-Dawley; D018709:Statistics, Nonparametric
chemical_list: D004731:Endotoxins; D015525:Fatty Acids, Omega-3; D018836:Inflammation Mediators; D010972:Platelet Activating Factor; D007975:Leukotriene B4; D015237:Dinoprost; D015232:Dinoprostone